NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
264
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO Discusses Measurable Progress on The Stock Day Podcast

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and specialty testing services for the worldwide life sciences and other industries, was featured on a recent episode of The Stock Day Podcast. PBI’s president and CEO, Richard T. Schumacher, joined Stock Day host Everett Jolly and offered a detailed update of measurable progress the company has made recently in multiple key areas. “Pressure has wonderful, very controllable properties. Unfortunately, scientists really have not had easy access to using pressure safely, especially high pressure, until we came along,” Schumacher said during the program. “We are developing three commercial technology platforms based on our 26 patents. The first one is called Pressure Cycling Technology (‘PCT’), the second is called BaroFold and the third is called Ultra Shear Technology (‘UST’). With PCT, we put the samples to be studied (like bacteria, viruses, cancer cells) in test tubes. We then place the tubes into a pressure chamber of one of our instruments. We need to determine the amount pressure we need to reach, how long it needs to be under that pressure, and how many times we want to cycle the pressure — that is, turn the pressure on and off — in order to open up the pathogen/cancer cell to release the important proteins and nucleic acids contained within, to be studied. This type of elegant control can’t be done nearly as well with heat processing — with heat, you basically get what you get when heating is done. Interestingly, every biological substance in nature has its own unique pressure point, and once you determine that pressure point, you can process that substance (pathogen, cell, enzyme, etc.) right up to the point where it will give you the best results, each and every time. Again, this is very hard to do with temperature and chemicals.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Pressure Biosciences (PBIO) Stock Research Links

PBIO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FRP Holdings, Inc. Set to Announce Q3 Earnings Soon

Updated Category News Views 63

FRP Holdings, Inc. Set to Announce Q3 Earnings Soon FRP Holdings, Inc. (NASDAQ: FRPH) is gearing up for an important update regarding their financial performance. The company is set to release its earnings results for the third quarter on an upcoming Wednesday. This announcement is keenly awaited by analysts and investors alike as it reflects the company's current...

Continue Reading
ACECO's Heartwarming Initiative Distributes Backpacks for Students

Updated Category News Views 126

ACECO Partners with United Way for Community Support In a remarkable effort to support local educational needs, ACECO has engaged its Hoist Up! Outreach Committee to collaborate with the United Way for the distribution of 250 backpacks filled with school supplies. This initiative demonstrates a strong commitment to helping students thrive as they return to school....

Continue Reading
Exploring Iovance Biotherapeutics' Recent Legal Challenges

Updated Category News Views 105

An Overview of Iovance Biotherapeutics Legal Issues Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has found itself in a challenging position following a recent class-action lawsuit. This situation has arisen due to allegations of securities fraud involving the company and its senior executives. The Class Action Lawsuit Explained The lawsuit, filed by a respected securities...

Continue Reading
Ross Gerber Offers Insightful Take on Tesla and Elon Musk

Updated Category News Views 154

Ross Gerber on His Views About Tesla and Elon Musk Ross Gerber openly shares his thoughts on the dynamic leadership of Elon Musk while at the same time being critical of some of the recent directions of Tesla. During a recent episode of the 'Chasing Finance' podcast, Gerber expressed his mixed feelings stating, “I’m not a fan of Elon.” However, he quickly added,...

Continue Reading
KLA Corporation Adjusts Price Target Yet Maintains Strong Outlook

Updated Category News Views 62

Revised Price Target and Market Insights for KLA Corporation KLA Corporation (NASDAQ: KLAC) has recently seen its stock target adjusted by Stifel to $800, down from $875. Despite this revision, the firm has retained a Buy rating for the company, reflecting confidence in its performance. Stifel noted that KLA exceeded expectations in its latest quarterly performance,...

Continue Reading